Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.
Location: United States, Massachusetts, Boston
Total raised: $112M
Investors 2
| Date | Name | Website |
| 10.07.2026 | 5AM Ventur... | 5amventure... |
| 09.02.2024 | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.11.2025 | - | $112M | - |
Mentions in press and media 4
| Date | Title | Description |
| 21.11.2025 | Lifordi Immunotherapeutics: $112 Million Raised With New Strategic Investment From Sanofi Ventures | Lifordi Immunotherapeutics, a clinical-stage biotechnology company advancing antibody-drug conjugates for autoimmune and inflammatory diseases, has secured a strategic investment from Sanofi Ventures along with additional funding from exist... |
| 19.11.2025 | Lifordi Immunotherapeutics: Strategic Investment Raised As Sanofi Ventures Joins $112 Million Round | Clinical-stage biotech company Lifordi Immunotherapeutics, which is focused on developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, announced that it has secured a strategic investment from Sanofi Ventures —... |
| 19.11.2025 | Lifordi Immunotherapeutics Raises Funding; Brings Total Raised to $112M | Lifordi Immunotherapeutics, a Burlington, MA-based clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, received an investment from Sanofi Ventures, ARCH Ventu... |
| - | Lifordi Immunotherapeutics | “Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) to develop treatments for autoimmune and inflammatory disorders.” |